Oncology CROs merging to offer broader range of services
- Chiltern, a UK-based contract research organization (CRO), has acquired 100% of North Carolina-based Ockham, also a CRO.
- The goal of the acquisition is to bolster Chiltern’s position in oncology, biopharmaceutical development and sourcing.
- Ockham will be merged into Chiltern; the new company will retain the name Chiltern.
The goal of the merger is to strengthen the new company’s position as a CRO with extensive oncology capabilities, to create a more powerful biopharmaceuticals division and to establish Chiltern as a Global Functional Service Provider (FSP).
Chiltern’s CEO Jim Eisenhart, PhD, will become the CEO of the newly established Chiltern Group, while Ockham’s CEO, James V. Baker, will become Chief Development Officer. “In Ockham’s continuing progression toward building the top niche oncology CRO, joining with Chilton has been an easy choice, allowing us to leverage Chiltern’s global reach and highly developed staffing business in Europe, both of which are complementary to Ockham’s deep oncology experience and source business in the US,” said Baker.
- www.chiltern.com Chiltern acquires Ockham and the companies merge operations